Thursday, October 7, 2010

Celldex Brain Cancer Vaccine Update – More Good News on Immunotherapy

The Celldex Therapeutics Inc. vaccine brain cancer received an encouraging result according to US Researchers. Patients with the brain cancer glioblastoma who were treated with this vaccine lived nearly twice as long as those who received radiation and chemotherapy.

This type of cancer often kills patients within a year; patients rarely survive more than three years. In this study, many patients are still alive after five years.

The Celldex Therapeutics Inc. vaccine works by targeting a mutation in a gene called the epidermal growth factor receptor, which fuels cancer growth.

The results were published in the Journal of Clinical Oncology online. Researchers contributing to the study were Dr. John Sampson of Duke University in conjunction with researchers from the University of Texas MD Anderson Cancer Center.

To read more about this study access the article on Thompson Reuters here.

You can also refer to The Journal of Clinical Oncology here.

For products to help alleviate unpleasant and uncomfortable side effects of radiation and chemotherapy treatment, please click here.